Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas, USA.
Pain Med. 2021 Oct 8;22(10):2224-2234. doi: 10.1093/pm/pnab054.
To examine the outpatient opioid prescribing practices and the factors associated with opioid prescriptions in patient visits with rheumatoid arthritis (RA).
This cross-sectional study used the 2011-2016 National Ambulatory Medical Care Survey. Descriptive weighted analyses were used to examine the trends in opioid prescribing practices for RA. Multivariable logistic regression was used to examine the factors associated with opioid prescriptions among RA visits.
Adult patients (>18 years of age) with a primary diagnosis of RA based on the International Classification of Diseases.
According to the national surveys, an average of 4.45 (95% confidence interval [CI], 2.30-6.60) million office visits were made annually for RA. Approximately 24.28% of these visits involved opioid prescriptions. The RA visits involving opioid prescriptions increased from 1.43 million in 2011-2012 to 3.69 million in 2015-2016 (P < .0001). Being in the age group of 50-64 years (odds ratio [OR] = 3.40; 95% CI, 1.29-9.00), being Hispanic or Latino (OR = 2.92, 95% CI, 1.10-7.74), visiting primary physician (OR = 4.67; 95% CI, 1.86-11.75), prescribing of muscle relaxants (OR = 64.32; 95% CI, 9.71-426.09), acetaminophen (OR = 93.40; 95% CI, 26.19-333.04), antidepressants (OR = 6.10; 95% CI, 2.63-14.14), and glucocorticoids (OR = 3.20; 95% CI, 1.61-6.38), were associated with an increased likelihood of receiving opioid prescriptions in RA.
One in four adult RA visits resulted in opioid prescriptions, and the opioid visits more than doubled during the study period. Several patient and provider factors were associated with the opioid prescribing among RA visits. Understanding these prescribing practices can help to devise strategies for safe opioid prescribing practices in RA.
研究门诊阿片类药物处方的情况,并分析与类风湿关节炎(RA)就诊中开具阿片类药物处方相关的因素。
本横断面研究使用了 2011-2016 年全国门诊医疗调查的数据。采用描述性加权分析方法来评估 RA 门诊阿片类药物处方的趋势。采用多变量逻辑回归分析方法来评估与 RA 就诊中开具阿片类药物处方相关的因素。
基于国际疾病分类标准,患有 RA 的成年患者(>18 岁)。
根据全国调查,每年平均有 445 万(95%置信区间[CI],230 万至 660 万)例 RA 门诊就诊。其中约 24.28%的就诊涉及阿片类药物处方。涉及阿片类药物处方的 RA 就诊量从 2011-2012 年的 143 万例增加到 2015-2016 年的 369 万例(P<0.0001)。年龄在 50-64 岁之间(比值比[OR] = 3.40;95%CI,1.29-9.00)、西班牙裔或拉丁裔(OR=2.92,95%CI,1.10-7.74)、就诊于初级保健医生(OR=4.67;95%CI,1.86-11.75)、开肌肉松弛剂(OR=64.32;95%CI,9.71-426.09)、对乙酰氨基酚(OR=93.40;95%CI,26.19-333.04)、抗抑郁药(OR=6.10;95%CI,2.63-14.14)和糖皮质激素(OR=3.20;95%CI,1.61-6.38)的患者,更有可能在 RA 就诊中开具阿片类药物处方。
四分之一的成年 RA 就诊会导致开具阿片类药物处方,在此期间,阿片类药物就诊量增加了一倍多。一些患者和医生的因素与 RA 就诊中开具阿片类药物处方相关。了解这些处方实践可以帮助制定安全的 RA 阿片类药物处方策略。